Table 1.
Baseline demographics and characteristicsa
| All patients (N = 532) |
Malignancy patients (n = 20) |
|
|---|---|---|
| Women | 301 (57) | 12 (60) |
| Adolescents | 28 (5) | 0 |
| Age, median (Q1, Q3), y | 33 (25, 45) | 52 (32, 65) |
| Follow-up, median (Q1, Q3), mo | 58 (34, 74) | 48 (17, 81) |
| No. of denosumab doses received, median (Q1, Q3) | 34 (18, 61) | 22 (11, 40) |
| GCTB disease type | ||
| Primary resectable | 168 (32) | 6 (30) |
| Primary unresectable | 94 (18) | 2 (10) |
| Recurrent resectable | 85 (16) | 2 (10) |
| Recurrent unresectable | 185 (35) | 10 (50) |
| Prior GCTB surgery | ||
| Yes | 276 (52) | 12 (60) |
| No | 256 (48) | 8 (40) |
| Prior GCTB radiotherapy | ||
| Yes | 52 (10) | 4 (20) |
| No | 480 (90) | 16 (80) |
GCTB giant cell tumor of bone, mo months, y years
aData are n (%) unless indicated otherwise